Medical and Pharmaceutical Industry - Market Research Report

 The global non-small cell lung cancer therapeutics market size is expected to reach USD 43.89 billion by 2030, registering a CAGR of 12.7% from 2024 to 2030, according to a new report by Grand View Research, Inc. The non-small cell cancer therapeutics (NSCLC) market is anticipated to witness significant growth during the forecast period. This can be attributed to the high investment by market players in the research and development of lung cancer therapy, presence of a rich pipeline, and increasing penetration of drugs during the forecast period.   Introduction of several drugs in various geographical regions is likely to drive the market during the forecast period. For instance, in October 2016, the FDA granted Breakthrough Therapy Designation to Alecensa (alectinib), a drug developed by Genentech to treat ALK-positive NSCLC as a first-line treatment. The drug has been approved in the U.S., Japan, Canada, Hong Kong, South Korea, Kuwait, and Israel.   Presence of a strong pipeline

 The global heavy construction equipment market size is expected to reach USD 289.3 billion in 2030 and is projected to grow at a CAGR of 5.2% from 2024 to 2030. Increased investment in infrastructure has been a major factor driving market growth.   Rise in infrastructural development around the world is the key catalyst that will propel market growth over the forecast period. Infrastructural development results in increased construction activities, which eventually creates a demand for heavy duty construction equipment. Developed infrastructure boosts economic growth by assisting cross-border trade and industrial growth.   Private financing is a key way to fund infrastructural development plans. For instance, infrastructure development in India has witnessed increased participation of private players in recent years. Moreover, the Indian government has increased its budget for infrastructural development.     Access the Heavy Construction Equipment Market Size, Share & Tre

 The global proton therapy systems market size is expected to reach USD 1.2 billion by 2030, growing at a CAGR of 7.3% from 2024 to 2030, according to a report by Grand View Research, Inc. The market is primarily driven by increasing number of proton therapy centers, rising number of cancer cases, and growing investments by hospitals to establish these centers.   Growing funds & investments by hospitals, manufacturers, and private investors are also contributing to the growth of this market. For instance, in August 2015, Mevion Medical Systems (U.S.) raised USD 200 million in an equity funding led by HOPU Investments (China) and YuanMing Capital (China). These funds are likely to be used for development of technologically advanced and low-cost products. Furthermore, governments across various geographies are including budgets for establishment of these centers. For instance, in July 2015, the state government of Victoria included nearly AUD 2 million (USD 1.53 million) to develop

The global bipolar disorder market is anticipated to reach USD 5.87 billion by 2030, growing at a CAGR of 2.7% from 2024 to 2030, according to a new report by Grand View Research, Inc. Government support for generating awareness about the bipolar disorder and technological advancements that facilitate accurate detection of a patient’s mood and mental state are a few of the factors driving the growth of this market.   The rising prevalence of bipolar disorders is likely to propel market growth in the forecast period. Government initiatives also drive the market growth. For instance, International Bipolar Foundation’s Social Security Disability Insurance (SSDI) or Supplemental Security Income (SSI) are programs offered by the Social Security Administration (U.S.) for the benefit of the people affected by bipolar disorder.     Access the Bipolar Disorder Market Size, Share & Trends Analysis Report By Type (Mood Stabilizer, Anticonvulsants, Antipsychotic Drugs), By Drug Clas

 The global targeted DNA RNA sequencing market size is expected to reach USD 34.56 billion in 2030 and is projected to grow at a CAGR of 19.4% from 2024 to 2030. Targeted Sequencing has emerged as a key technology in life science research by enabling examination of a specific region of interest while keeping the seq. cost as well as the complexity of data under manageable limits.   This approach enhances sequencing depth by allowing the evaluation of specific coding regions within genes or specific genes, which are known to harbor mutations for disease pathogenesis. Several research projects have employed this technology to avoid wastage of information and extra cost and study only relevant genes. The number of such projects continues to grow, consequently driving the market.   Innovations to address the pitfalls of targeted enrichment methods are anticipated to enhance the usage rate of this technology throughout the forecast period. Moreover, with a decrease in seq-cost and impro